Zoetis completes acquisition of Nexvet BiopharmaAugust 8, 2017Zoetis Inc., manufacturer of veterinary vaccines and medicines for veterinarians, livestock producers, farmers, and pet owners, announced the completion of its $85 million acquisition of Nexvet Biopharma, a Tullamore, Ireland-based company that manufactures monoclonal antibodies (mAb) for companion animal pain management.
SPONSORED CONTENTDon't just protect. Triple protect.One tasty monthly chew. Approved for puppies as young as 8 weeks, weighing at least 2.8 lbs. + Learn more